ABSTRACT-The effects of K+ channel openers (PCOs), NIP-121, levcromakalim and nicorandil, and the blockers of the specific binding sites for [3H]glibenclamide, ATP-sensitive K+ channel blocker, were investigated in rat brain and cardiac ventricle membrane preparations. When the microsomes were incubated with [3H]glibenclamide, the specific glibenclamide binding was fully inhibited by unlabeled glibenclamide (1 pM) and apamin (100 pM). However, the specific glibenclamide binding was not influenced by excess NIP-121, levcromakalim and nicorandil, although glibenclamide antagonized the increase in the 86Rb+ efflux by PCOs. On the other hand, the binding of [3H]glibenclamide after a long pre-incubation (60 min) at 37'C with NIP-121 and levcromakalim at pharmacological effective concentrations (10 nM to 1 pM) was significantly influenced. Both PCOs partially reduced both Kd and Bmax values of the specific [3H]-glibenclamide binding in a concentration-dependent manner that was not regulated by GTPIS. The doseeffect relationships for the Bmax's of NIP-121 and levcromakalim seemed similar to those for vasorelaxation. These findings indicate that the pharmacological effect of PCO may be caused by the binding to its own specific sites but not to the specific sulfonylurea sites. The binding of PCOs may inhibit, in a negative allosteric manner the binding of sulfonylureas.
Sulfonylurea derivatives such as glibenclamide and tolbutamide, which are clinically applied as orally active antidiabetic agents, are specific blockers for the ATP-sensitive potassium current (IK(ATP)). On the other hand, potassium channel openers (PCOs) specifically activate IK(ATP)' resulting in the increase of potassium ion permeability through the cell membrane (1, 2) . Glibenclamide was reported to competively antagonize the relaxation of the rat aorta (3 -6) , rat portal vein (4, 7) and guinea pig pulmonary artery (8) and the negative inotropic action of the canine atrial muscle (9) induced by PCOs such as NIP-121 (4 -6), cromakalim (3 -9) , pinacidil (8, 9) , minoxidil sulfate (7), RP 49356 (8) and nicorandil (9) . In addition, the shortening of the action potential duration in the guinea pig ventricular cells with intracellular adenosine triphosphate (ATP) depletion, which is due to the activation of IK(ATP)' was reportedly inhibited by glibenclamide (10) . In the canine atrial muscle, non-sulfonylureas tetraethylammonium (TEA), tetrabutylammonium (TBA) and BaC12 at low concentrations (<I mM), but not TEA at a high concentration (3 mM), were reported to competively antagonize the negative inotropic effect of cromakalim and pinacidil (11) . On the other hand, Orito et al. reported that TEA and TBA non-competively inhibited the levcromakalim-induced relaxation of the canine coronary artery (12) . They suggested that TEA and TBA blocked the effect of PCOs by binding to a possible high-affinity site for tetraalkylammonium in the canine coronary artery (12) . The slopes of the Schild plots provided proof for the above-mentioned competitive antagonisms. Therefore, the relationship between PCO and sulfonylurea derivatives is akin to that between agonists and antagonists, which is based upon classical pharmacological theory. However, in earlier receptor binding studies, PCOs reportedly did not displace the specific [3H]-glibenclamide binding in the competition assay protocol (13, 14) . In addition, Bray and Quast (15) and Quast et al. (16) suggested that sulfonylurea derivatives inhibited in a negative allosteric manner the specific binding of PCO on the ATP-sensitive potassium channels.
In this study, the effects of PCOs, such as the pyranobenzoxadiazol derivative NIP-121 that is about 10 times more potent than the benzopyran derivative cromakalim (4-6, 17-20), levcromakalim ((-)-enantiomer of cromakalim) and nicorandil, on the specific binding sites for [3H]glibenclamide in rat brain and ventricle membrane preparations were thoroughly examined by not only the competition assay but also the saturation assay protocol. In addition, the properties of the specific binding sites for [3H]glibenclamide were characterized by using the above-described potassium channel blockers and by using phentolamine, which is reported to be an antagonist for PCO (21 -23) .
MATERIALS AND METHODS
Male Wistar rats, each weighing 290 to 410 g, were purchased from Charles River Japan (Kanagawa). All animals were sacrificed by venesection under deep anesthesia induced by an intravenous injection of an excess of sodium pentobarbital.
Membrane preparations of the rat aorta, heart and brain
Crude membrane preparations of the rat aorta, heart and brain were prepared according to a modified procedure based on an earlier method (24), as follows: The tissues were dissected, and then adherent fat and connective tissue were removed from them in oxygenated Krebs-Henseleit solution (371C) of the following composition: 118.4 mM NaCI, 4.7 mM KCI, 1.2 mM MgSO4, 2.5 mM CaC12i 1.2 mM KH2PO4, 25.0 mM NaHCO3 and 11.7 mM glucose. The pooled tissues were finely minced with scissors and homogenized in 20 volumes of ice-cold 50 mM TrisHCl buffer (pH 7.4) by ten 5-sec bursts on the Polytron (Kinematica, Lucern, Switzerland) at a setting of 7. The homogenate was centrifuged at 48,000 x g for 60 min at 4 C . The pellet was resuspended in ice-cold Tris-HC1 buffer by a 2-sec burst on the Polytron. This washed suspension was again sedimented by centrifugation at 48,000 x g for 60 min at 41C, and the final pellet was resuspended as described above, to a concentration of about 5 mg protein/ml Tris-HC1 buffer. The crude membrane preparations were stored at -80'C until use. The protein concentration was determined by the method of Lowry et al. (25) , with bovine serum albumin (Sigma Chemical Co., St. Louis, MO, USA) as the standard.
Receptor binding studies
The crude membrane preparations (aorta, 0.071 mg protein/ml; heart, 0.35 mg protein/ml; brain, 0.23 mg protein/ml) and [3H]glibenclamide (0.0625 to 2 nM) were incubated for 20 min at 251C in the presence or absence of 10 pM unlabeled glibenclamide in a total volume of 0.3 ml. In a part of the study, the membrane preparations from rat brain and [3H]glibenclamide at the same concentrations were incubated for 20 min at 371C after preincubation of NIP-121 (1 to 300 nM), levcromakalim (3 to 1000 nM) or the vehicle as the control for 60 min, in the presence or absence of 100 pM guanosine 5'-O-(3-thiotriphosphate) (GTP1S). The incubation mixture was diluted with 5 ml of ice-cold Tris-HCl buffer, vacuumfiltered through glass fiber filters (GF/C; Whatman, Maidstone, UK) and washed with 20 ml of ice-cold buffer at a flow rate of 1 ml/sec. The filters were then dried and placed in scintillation vials containing 5 ml scintillator (Econo-fluor; New England Nuclear, Boston, MA, USA) for at least 3 hr. The radioactivity was measured in a liquid scintillation counter (Tri-Carb 340CD; Packard, Zurich, Switzerland) at an efficacy of 45010. The specific binding of [3H]glibenclamide was defined as the total binding minus the blanks determined in the presence of 10 pM unlabeled glibenclamide. The [3H]glibenclamide dissociation constant (Kd) and the maximum number of specific binding sites (Bma) were computed by Scatchard analysis (26) for a single class of receptor sites or a non-linear least squares program for two or multiple classes of receptor sites.
To study the displacement of specific [3H]glibenclamide receptor binding by other unlabeled compounds, the crude membrane preparations and [3H]glibenclamide (1 nM for brain preparation and 0.5 or 2 nM for ventricle preparation) were incubated with increasing concentrations of NIP-121, levcromakalim, nicorandil, unlabeled glibenclamide, TEA and 4-aminopyridine (4-AP) for 20 min at 0, 25 or 371C. Thereafter, the binding was studied as described above. The apparent K; values were determined from the formula of Cheng and Prusoff (27) , K;= IC50/(1 + L/Kd), where L =the radioligand concentration, and the apparent Hill coefficient or slope factor of the drug was determined from Hill or pseudo Hill plots, respectively (28) .
Effects on 86Rb+ efflux
The thoracic aortas were dissected free of adherent fat and connective tissue and then cut into spiral strips, 3 mm in width and 15 mm in length, in modified Krebs solution (MKS) of the following composition: 121.9 mM NaCI, 4.7 mM KCI, 2.5 mM CaC12i 1.2 mM MgC12, 1.2 mM KH2PO4, 15.5 mM NaHCO3 and 11.5 mM glucose, which was heated to 37V and bubbled with 95010 O2/5010 C02-The endothelium of all preparations was removed using a cotton stick. The 86Rb+ efflux procedures were essentially as described by Hamilton et al. (29) . After a 60-min equilibration period in the bathing solution maintained at 371C and gassed with 5010 CO2 in 02, tissues were loaded with 86Rb+ (74 kBq/ml) for 90 min. The 86Rb+ was then allowed to flow from the tissue into non-radioactive MKS. The tissues were transferred to 2 ml of fresh solution every 2 min. Thirty minutes after the start of efflux, the tissues were exposed to a solution containing NIP-121 (100 nM) or NIP-121 and glibenclamide (10-100 nM). At the end of the efflux study, the strips were placed in 0.5 ml Soluene-350 (Packard) at 501C for 3 hr. The dissolved samples and 0.1 ml aliquots of the bathing solution were added to 5 ml of Hionic-Fluor (Packard) scintillation fluid, and the radioactivity was measured.
Effects on vasorelaxant effect
In the tissue bath study, the isolated thoracic aorta was cut into a spiral strip, 3 x 15 mm, in Krebs Henseleit solution at 37V bubbled with 95% 02/5% C02, and the endothelium was removed. Isometric tension was recorded under a resting tension of 1 g (TB-611T; Nihon Kohden, Tokyo). The aortic strips were contracted with a sub-maximal concentration (final concentration, 30 mM) of hypertonic KCl after the equilibration. NIP-121 or levcromakalim was cumulatively added to the preparation in half log unit increments after the contractile responses reached a plateau. At the end of the study, 100 pM papaverine was added to induce maximum relaxation. The degree of relaxation produced is expressed as a percentage of the maximum induced by papaverine. 
RESULTS
Identification of [3HJglibenclamide specific binding sites in the membranes from rat brain, heart and aorta
[3H]Glibenclamide bound reversibly and saturably to membranes from the rat brain and heart (< 20 min) (data not shown). The saturation isotherms indicated specific and saturable binding sites for [3H]glibenclamide ( Fig. 1) , with non-specific binding representing less than 20010 of
Drugs
The following compounds were used: NIP-121, levcromakalim and nicorandil which were synthesized at the Central Research Laboratories of Nissan Chemical Industries, Ltd., Chiba; glibenclamide, TEA chloride, apamin, 4-AP, GTP1S and papaverine (Sigma Chemical Co.); phentolamine mesilate (Regitin inj.; Ciba Geigy Japan, Takarazuka). NIP-121 and levcromakalim (3 x 10-'M) were dissolved in 50010 dimethyl sulfoxide (DMSO) and serially diluted with distilled water. Nicorandil and phentolamine were dissolved in distilled water. Glibenclamide, TEA, apamin and 4-AP were dissolved in DMSO. The final concentrations of DMSO were from 1.7 x 10-8 to 0.17%. The vehicle used did not influence the binding of [3Hlalibenclamide.
Radioactive labeled ligands
, with a specific activity of 1883.3 GBq/mmol (radiochemical purity, 99%), and 86RbC1, with a specific activity of 730 GBq/g (radiochemical purity, >99%), were purchased from DuPont-NEN (Boston, MA, USA). The [3H]glibenclamide, supplied in ethanol, was further diluted in distilled water. The final concentrations of the vehicle were from 0.003 to 0.1010. 86RbC1 was supplied in a 0.5 M HCl solution and further diluted with distilled water.
Statistical analyses
In the saturation assay, the data were analyzed by (Fig. 2) or that in rat ventricle membrane at concentrations of 0.5 or 2 nM [3H]glibenclamide, respectively (Fig. 3) . tion (Fig. 5 ).
Displacement properties of various potassium channel blockers on [3H]glibenclamide specific binding
Not only the unlabeled IK(ATP) blocker glibenclamide, but also the small conductance calcium-activated potassium channel (ISK(Ca)) blocker apamin (30) , fully displaced the specific binding of [3H]glibenclamide in both membrane preparations in a concentration-dependent manner (Fig. 6) . The voltage-dependent potassium channel blocker 4-AP and TEA in a pharmacologically effective concentration range (10 to 30 mM) partially inhibited the specific binding of [3H]glibenclamide, especially in the ventricle membrane. The slope factors from the competition of unlabeled glibenclamide at all concentrations on brain and ventricle membranes were 0.502 (r=0.984, P<0.01, means of three separate experiments performed in triplicate) and 0.400 (r=0.970, P<0.05), respectively, which indicate dual classes of binding sites for [3H]glibenclamide. In the brain preparation, the result from the saturation assay was inconsistent with that from the competition assay. This discrepancy might be caused by the use of glibenclamide at different concentration ranges in the experimental protocols. If [3H]glibenclamide of much higher concentrations (more than 10 nM) was used in a saturation as- for each blocker were not identified in this study.
;ay, dual classes of sites might be obtained in brain membrane preparations. The apparent inhibition constants ;pK;) of high and low affinity sites in the brain membrane were 11.40 and 9.83, respectively, and those in the ventri-;le membrane were 10.9 and 6.82, respectively. In the venricle membrane, the slope factors from the curves of ;libenclamide above about 10-'M, apamin and 4-AP were similar, being 1.18, 1.32 and 1.22, respectively. In addition, the slope factors from the curves of glibenclamide it concentrations below about 10' M and TEA were also ;omputed to be about the same values, being 0.47 and ).58, respectively. The apparent K; of the potassium chancel blockers were not calculated because the binding sites
The effect of phentolamine on [3HJglibenclamide specific binding Phentolamine, an a,-adrenoceptor antagonist that antagonizes the effect of PCOs (4, 21-23), did not displace
[3H]glibenclamide specific binding in the rat brain or ventricle membranes (Fig. 6 ).
The antagonism of glibenclamide and apamin against the NIP-121-induced 86Rb+ efflux increment NIP-121 (100 nM) significantly increased the rate of 86Rb+ efflux above the basal level . Glibenclamide at 10 to 100 nM and apamin at the excess concentration of 10 ,uM significantly inhibited this increase in the rate of 86Rb+ efflux in a concentration-dependent manner (Fig. 7) . The maximum inhibition occurred in the presence of 50 nM glibenclamide. The pD2 value of glibenclamide for the inhibition of 86Rb+ efflux increased by NIP-121 was 7.98±0.75 (mean±S.E.M.
of five experiments).
DISCUSSION
Identification of [jHJglibenclamide specific binding sites in the membranes from rat brain, heart and aorta Specific binding sites for [3HIglib enclamide were identified in membranes prepared from rat brain and heart. The sites of rat brain membrane determined from the saturation assay are consistent with the high affinity sites in the ventricle membrane, because their Kd values were similar. The computed Kd value of glibenclamide for the high affinity sites was the same as that previously reported, e.g., Kd values for intestinal smooth muscle (31), insulinoma cells (32) (33) (34) and the cerebral cortex (14, 31, 32, 35) . In both preparations, unlabeled glibenclamide displaced the specific binding of [3H]glibenclamide in a concentration-dependent manner. However, the slope factor from the competition of unlabeled glibenclamide on brain membranes was less than 1, which indicates dual classes of binding sites for [3H]glibenclamide, which is in agreement with an earlier report (14) . The discrepancy might be caused by the use of glibenclamide at different concentration ranges in the two experimental protocols. We confirmed that [3H]glibenclamide also binds to a single class of binding sites in the brain membrane in the saturation assay examined at a wider concentration ranges (0.0625 to 10 nM) (data not shown).
In the present study, we failed to obtain specific binding sites for glibenclamide in the microsomal, cultured smooth muscle cell and tissue-strip preparations of rat, rabbit and canine aorta (unpublished observations). This may be due to the slow dissociation rate of glibenclamide from the specific sites, because in brain and ventricle preparations, PCOs could not displace the bound glibenclamide but inhibited the glibenclamide binding. Furthermore, antagonistic actions of glibenclamide on PCO-induced 86Rb+ efflux indicates the presence of specific sites of actions of glibenclamide in the rat aorta. Therefore, we conclude that glibenclamide is not a suitable ligand for studies on specific PCO binding sites in rat aorta. It may be necessary to use a radiolabeled ligand with higher affinity such as
[3H]propyl-N"-3-pyridinylguanidine) (15, 16) in binding studies not only for PCOs but also for potassium channel blockers, especially in blood vessels.
The effects of NIP-121, levcromakalim and nicorandil on [jHJglibenclamide specific binding
The effects of PCOs such as NIP-121, levcromakalim and nicorandil are competitively antagonized by sulfonylurea IK(ATP) blockers such as glibenclamide or tolbutamide (3-9, 13, 17, 36, 37) , which yielded a slope of 1 on the Schild analysis. Therefore, if we assume that PCO and sulfonylurea are the competitive agonist and antagonist for the ATP-sensitive potassium channel, respectively, the binding sites for PCO and sulfonylurea should be the same. However, in this study, NIP-121, levcromakalim and nicorandil, which reportedly open ATPsensitive potassium channels, did not displace the specific binding of [3H]glibenclamide in rat brain and ventricle membranes when the membrane and [3H]glibenclamide were simultaneously incubated with the PCOs. These findings are in agreement with those obtained earlier using PCOs such as cromakalim and diazoxide, but not RP 49356, at higher concentration ranges (13, 14) . In this study, NIP-121 and levcromakalim also did not compete for either type of binding site in the rat ventricle membrane at 0 C . These findings suggest the following: The specific binding site for PCOs is completely different from that for sulfonylureas, because the same phenomenon was observed using different PCOs such as benzopyran or a nicorandil-like structure. Recently, the specific binding sites for sulfonylureas and ATP-sensitive potassium channels were reported to be separate molecular entities, since the cloned channels were not inhibited by a micromolar concentration of glibenclamide, although they were activated by the PCO pinacidil (38, 39) . In addition, Bray and Quast (15) This study showed that the ISK(Ca) selective blocker apamin (30) also displaced the specific binding of [3H]glibenclamide in both membrane preparations in a concentration-dependent manner. However, apamin at the nanomolar range may not bind to the sulfonylurea binding sites or block IK(ATP), because the effective concentration range for the binding (> 10-6 M) was about 100-times higher than that for pharmacological ISK(ca) channel blockade. In this study, apamin at 10 pM but not at 10 nM significantly inhibited the NIP-121 (100 nM)-induced 86Rb+ efflux increment. In addition, Calder et al. reported that apamin at 1 pM did not influence the cromakalim-induced 86Rb+ efflux increment in isolated guinea pig resistant arteries (43) . This suggests that apamin at a high concentration (> 10 pM) may influence the function of IK(ATP). The full displacement and the slope of the competitive curve indicated that apamin directly binds to sulfonylurea sites, but does not cause negative allosteric regulation of specific sulfonylurea sites. However, it is not clear at present where the chemical homology lies, although sulfonylurea- (44, 45) and apamin-(46, 47) receptor proteins have been purified and identified. Some parts of the binding sites for these blockers might hold some analogous amino acid sequences or a similar electric charge relationship. In addition, we also found that the voltage-dependent potassium channel blocker 4-AP and TEA in the concentration range that produces a pharmacological response significantly displaced the specific [3H]glib enclamide binding, especially in rat heart.
The effect of phentolamine on [3H]glibenclamide specific binding Phentolamine antagonizes the actions of cromakalim (4, (21) (22) (23) . According to our earlier report (4), glibenclamide (10-7 M) and phentolamine (3 x 10-6, 3 x 10-5 M) also antagonized the relaxation induced by NIP-121 and cromakalim. The present findings are the first to show that phentolamine did not displace [3H]glibenclamide from its specific binding sites in both the rat brain and heart. The pharmacological antagonism of phentolamine on the PCO-effect might be irrelevant to the binding for the specific sites of glibenclamide. The antagonism is reportedly caused by its chemical structure (imidazol-(id)ine derivative) and not by blockade of a,-adrenoceptors (4, (21) (22) (23) . Phentolamine might bind to the other specific receptors related to the PCO-induced response. 
